Child health and education outcomes in children with Hirschsprung disease: a population-based data linkage study in England
Abstract
Hirschsprung disease (HSCR) is a rare congenital intestinal condition that, despite lifesaving surgery, can result in a lower quality of life throughout childhood and into adulthood. There is a lack of population-level research on the reasons why children with HSCR are frequently hospitalised throughout childhood, or on school experiences. We used linked administrative data from health and education services (ECHILD) to create a cohort of births from 2002–2020. We evaluated admission and mortality rates, number of surgical procedures, and reasons for admissions for children with and without HSCR at ages 0-14. We assessed how many children had recorded Special Educational Needs by Year 1 of primary school (age 6). Of the 11,261,227 children in our cohort, 3227 (0.03%) had HSCR. 95.0% of children with HSCR were readmitted by age 4 compared with 40.2% of those without. Across ages and sexes, children with HSCR were frequently admitted for constipation, gastroenteritis, intestinal infections, abdominal pain, and nausea and vomiting. 44.0% of children with HSCR had recorded Special Educational Needs by age 6 compared with 17.9% of those without HSCR. Improvements to treatment success, including novel or complementary approaches, are required in order to improve quality of life for children with HSCR. Further research is needed to understand the impact of HSCR and its treatment at the transition from paediatric to adult services, and on child development, progress in school, and…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 11,261,227 participants or records.
Read the paper
Related studies
- Patient-Centered Pharmaceutical Design to Improve Acceptability of Medicines: Similarities and Differences in Paediatric and Geriatric Populations
- Evidence-based clinical practice guidelines for irritable bowel syndrome 2020
- Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial
- Gastrointestinal manifestations in COVID-19
- COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist
- Persistent gut barrier damage and commensal bacterial influx following eradication of Giardia infection in mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.